CymaBay Therapeutics Inc. (NASDAQ:CBAY) – Investment analysts at SunTrust Banks issued their Q1 2018 earnings per share (EPS) estimates for shares of CymaBay Therapeutics in a research note issued to investors on Tuesday. SunTrust Banks analyst E. Nash expects that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter. SunTrust Banks currently has a “Buy” rating and a $15.00 price target on the stock. SunTrust Banks also issued estimates for CymaBay Therapeutics’ Q3 2018 earnings at ($0.26) EPS and Q4 2018 earnings at ($0.28) EPS.

A number of other research analysts have also issued reports on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. Oppenheimer Holdings, Inc. set a $15.00 target price on CymaBay Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Piper Jaffray Companies reissued a “buy” rating and issued a $12.00 target price on shares of CymaBay Therapeutics in a report on Friday, October 27th. Zacks Investment Research raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 18th. Finally, Leerink Swann assumed coverage on CymaBay Therapeutics in a report on Wednesday, August 23rd. They issued an “outperform” rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $14.00.

WARNING: “SunTrust Banks Comments on CymaBay Therapeutics Inc.’s Q1 2018 Earnings (CBAY)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/suntrust-banks-comments-on-cymabay-therapeutics-inc-s-q1-2018-earnings-cbay/1704414.html.

CymaBay Therapeutics (NASDAQ:CBAY) opened at $8.35 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics has a twelve month low of $1.46 and a twelve month high of $9.40.

CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). During the same quarter last year, the business earned ($0.25) earnings per share.

In related news, Director Kurt Von Emster sold 108,876 shares of the company’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total transaction of $854,676.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Charles Mcwherter acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were acquired at an average cost of $8.67 per share, for a total transaction of $43,350.00. Following the acquisition, the senior vice president now directly owns 10,300 shares of the company’s stock, valued at $89,301. The disclosure for this purchase can be found here. Insiders have sold 447,257 shares of company stock worth $3,730,862 in the last ninety days. 15.10% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 140 shares during the period. Marshall Wace North America L.P. acquired a new position in CymaBay Therapeutics during the second quarter worth $242,000. Boothbay Fund Management LLC acquired a new position in CymaBay Therapeutics during the third quarter worth $404,000. Ardsley Advisory Partners grew its holdings in CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 20,000 shares during the period. Finally, Crestline Management LP acquired a new position in CymaBay Therapeutics during the third quarter worth $841,000. 27.08% of the stock is currently owned by hedge funds and other institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.